More than double the success rate of conventional treatment
Diante de um dos cânceres mais letais que a medicina conhece, o Brasil deu um passo significativo: a Anvisa aprovou o ONIVYDE, uma formulação lipossomal de irinotecano destinada a pacientes com câncer pancreático avançado que já esgotaram as opções convencionais. A tecnologia que envolve o princípio ativo em uma membrana lipídica não é apenas uma inovação técnica — é uma resposta humana à brutalidade de uma doença que raramente concede tempo. Com o dobro da taxa de controle da terapia padrão em ensaios clínicos, essa aprovação não promete cura, mas oferece algo igualmente precioso: a possibilidade de mais tempo.
- O câncer pancreático metastático é implacável — a maioria dos pacientes que chegam a esse estágio já não responde aos tratamentos disponíveis, e o tempo se torna o recurso mais escasso.
- A aprovação do ONIVYDE pela Anvisa em 28 de abril de 2025 representa uma ruptura real: 52% de controle da doença contra apenas 24% com a quimioterapia convencional em um ensaio com mais de 400 pacientes.
- A tecnologia lipossomal permite que o medicamento circule por mais tempo no organismo, concentre-se melhor nos tumores e reduza os efeitos colaterais devastadores que tornam a quimioterapia tão difícil de suportar.
- Mais de 25% dos pacientes tratados com ONIVYDE sobreviveram ao menos um ano após o início do tratamento — um marco expressivo para uma doença que raramente concede essa margem.
- Publicada no European Journal of Cancer e respaldada por revisão por pares, a evidência que sustenta essa aprovação é sólida o suficiente para transformar o que é possível oferecer a quem mais precisa.
A Anvisa aprovou na segunda-feira, 28 de abril, o ONIVYDE para pacientes com câncer pancreático avançado que não respondem mais aos tratamentos convencionais. O medicamento é uma versão reformulada do irinotecano — agente quimioterápico usado há décadas — mas com uma diferença decisiva: o princípio ativo é encapsulado em uma membrana lipídica, o que retarda sua eliminação pelo organismo e permite que chegue aos tumores em concentrações mais elevadas.
A aprovação se apoia em evidências clínicas robustas. Em um ensaio com mais de 400 pacientes com tumores pancreáticos metastáticos resistentes ao tratamento, o ONIVYDE combinado a outros dois quimioterápicos alcançou 52% de controle da doença — mais que o dobro dos 24% observados com a terapia convencional. Para quem enfrenta um dos cânceres mais letais da medicina, essa diferença representa a distância entre a esperança e a resignação.
Além de ampliar a eficácia, a encapsulação lipossomal reduz parte dos efeitos colaterais que tornam a quimioterapia tão difícil de tolerar: o tumor recebe uma dose mais concentrada enquanto o organismo absorve menos dano colateral. Os dados de sobrevivência reforçam esse quadro — mais de 25% dos pacientes tratados com ONIVYDE sobreviveram ao menos um ano após o início do tratamento, um marco significativo diante de uma doença que, em estágio avançado, raramente concede essa margem.
O ONIVYDE não é uma cura. Mas é uma opção substancialmente melhor do que o que existia antes — e em oncologia, substancialmente melhor pode significar a diferença entre meses e anos.
Brazil's health regulator has approved a new weapon against one of cancer's most aggressive forms. On Monday, April 28, the Anvisa—the country's national health surveillance agency—cleared ONIVYDE for use in patients with advanced pancreatic cancer that has stopped responding to standard treatments. The drug is a reformulated version of irinotecan, a chemotherapy agent doctors have used for decades against colorectal and other cancers. What makes this version different is its delivery mechanism: the active ingredient is wrapped in a lipid membrane, a technology that slows how quickly the body eliminates the drug and allows it to reach tumors in higher concentrations.
The approval rests on solid clinical evidence. Researchers tested ONIVYDE combined with two other chemotherapy drugs in a trial involving more than 400 patients with metastatic, treatment-resistant pancreatic tumors. The results were striking. Among patients receiving conventional therapy alone, only 24 percent achieved disease control—meaning their cancer stopped advancing. Those treated with ONIVYDE reached a 52 percent control rate, more than double the conventional outcome. For patients facing one of medicine's most lethal cancers, that difference is the distance between hope and resignation.
The liposomal encapsulation does more than boost efficacy. By keeping the drug circulating longer in the bloodstream, it allows the medication to work for extended periods while reducing some of the brutal side effects that make standard chemotherapy so difficult to endure. The tumor receives a more concentrated dose while the patient's body absorbs less collateral damage. It is a refinement born from decades of understanding how cancer drugs move through the body.
Survival data reinforces the clinical picture. More than 25 percent of patients treated with ONIVYDE survived at least one year after starting the drug—a significant milestone when dealing with aggressive metastatic disease. For context: pancreatic cancer in its advanced stages is relentless. Most patients who reach that point have already exhausted their options. Standard protocols fail. Time becomes the enemy. A drug that extends survival by months, that gives more than one in four patients a full year beyond diagnosis, represents a genuine shift in what is possible.
The approval was published in the European Journal of Cancer, lending it the weight of peer review and international scrutiny. Anvisa's decision reflects not just hope but evidence—the kind that regulators require before they allow a new drug into the market. For the patients and families who have watched pancreatic cancer advance despite treatment, this approval opens a door that was previously closed. It is not a cure. It is not a guarantee. But it is a substantially better option than what existed before, and in oncology, substantially better can mean the difference between months and years.
Citas Notables
The liposomal encapsulation allows the drug to reach tumors in higher concentrations while reducing side effects compared to standard chemotherapy— Clinical trial data published in European Journal of Cancer
La Conversación del Hearth Otra perspectiva de la historia
Why does the liposomal wrapping matter so much? It sounds technical, but what does it actually do for the patient?
It's about getting the poison to the right place. Standard chemotherapy floods the whole body—it kills cancer cells but also damages healthy tissue. This lipid coating acts like a slow-release capsule. The drug stays in circulation longer, which means it reaches the tumor in higher concentration while the rest of your body gets exposed to less of it. You get more effect where you need it, less damage everywhere else.
The numbers are striking—52 percent versus 24 percent. But what does disease control actually mean? Does it mean the cancer goes away?
No, it means the cancer stops growing. In advanced pancreatic cancer, stopping the progression is often the best you can hope for. You're not curing it; you're buying time. You're keeping it from spreading further while the patient lives their life.
And the one-year survival rate—more than 25 percent. Is that actually good for pancreatic cancer?
For advanced metastatic pancreatic cancer, yes. This is a disease that kills most people within months. Getting more than a quarter of patients to the one-year mark is substantial. It means some people get to see another season, spend more time with family, make plans they thought were impossible.
Why did it take so long to reformulate irinotecan? The drug itself has been around for decades.
Because the science of drug delivery is hard. You have to understand how the body processes the drug, how to protect it, how to release it at the tumor site. It's not just chemistry; it's engineering at the molecular level. And you have to prove it works in humans, which takes years and hundreds of patients.
What happens to patients who don't respond to ONIVYDE?
That's the honest part. Not everyone benefits. Some patients' cancers are too aggressive, too resistant. But for those 52 percent who do respond, the drug works. And for the 24 percent who would have responded to conventional therapy anyway, they now have a better option. The approval doesn't solve pancreatic cancer. It just makes the fight less one-sided.